On March 26, 2009 FDA sent Untitled Letters to 14 companies identifying Internet activities that violated the Federal Food Drug & Cosmetic Act — creating 45 misbranded products. Soon after, on May 27, 2009, FDA released a 27-page draft guidance “Presenting Risk Information in Prescription Drug and Medical Device Promotion” to explain how FDA now evaluates prescription drug/biologic and device promotional pieces for adequate presentation of risk information.
How will these new expectations change your company’s website and web-based advertising? And with this FDA-initiative progressing so quickly, what should you do now to comply in this strict and fast-changing regulatory environment?
On Thursday, July 9, beginning at 1:00 p.m. EDT, join FOI Services and FDA-regulatory specialist Dr. Joshua Sharlin, attorney Mr. Arnie Friede and internet marketing strategist Ms. Carlen Lea Lesser for a 90-minute teleconference discussing these developments and how they will affect your Internet presence.
Take advantage of the advice of this experienced panel of experts to review your website, online advertising and email outreach…before FDA examines it for you.
SIGN UP to participate in the teleconference at http://www.foiservices.com/tc/